Table 1 Demographics of the samples analysed in the targeted assay (phase I)

From: Plasma proteomics identify biomarkers predicting Parkinson’s disease up to 7 years before symptom onset

 

De novo PD

Healthy controls

Other neurological disorders (OND)

REM sleep behaviour disorder (iRBD)

p value (compared to healthy controls)

De novo PD

iRBD

OND

Number of subjects

99

36

41

18

   

Sex (M/F)

49/50

20/15

29/12

10/8

   

M/F%

49/51

57/43

71/29

56/44

   

Age (mean ± SD)

67.1 ± 10.6

63.7 ± 6.5

70 ± 8.9

67.3 ± 8.3

8.3E-2

8.9E-2

8.4E-4

Range

41−87

52−77

49−82

51−77

   

UPDRS I (mean ± SD)

1.8 ± 1.8

0.5 ± 0.9

N/A

2.9 ± 2.5

6.1E-5

4.6E-6

N/A

Range

0−8

0−4

N/A

0−9

   

UPDRS II (mean ± SD)

8.7 ± 6.6

0.03 ± 0.2

N/A

3.1 ± 3.7

1.9E-12

1.4E-5

N/A

Range

0−29

0 − 1

N/A

0−11

   

UPDRS III (mean ± SD)

24.8 ± 13.9

0.3 ± 0.7

21.2 ± 13.3

2.6 ± 2.7

7.1E-19

1.6E-5

1.7E-13

Range

5−69

0−3

3−51

0−10

   

UPDRS total score (mean ± SD)

35.2 ± 18.3

0.7 ± 1.3

N/A

8.5 ± 7.2

1.4E-20

8.9E-8

N/A

Range

6−86

0−6

N/A

1−26

   

MMSE total score (mean ± SD)

28 ± 2.2

28.9 ± 1.4

26.6 ± 2.6

28.5 ± 1.8

2.8E-2

3.6E-1

2.5E-5

Range

25−30

26–30

19−30

25−30

   
  1. OND consists of subjects with vascular parkinsonism (n = 10), essential tremor (n = 7), progressive supranuclear palsy; PSP (n = 7), multiple system atrophy; MSA (n = 3), corticobasal syndrome; CBS (n = 2), dementia with Lewy bodies; DLB (n = 2), drug-induced tremor (n = 2), dystonic tremor (n = 2), restless legs syndrome (n = 1), hemifacial spasm (n = 1), motoneuron disease (n = 1), amyotrophic shoulder neuralgia (n = 1), Alzheimer’s disease (n = 1). The significance between controls and the disease groups was tested by applying Student’s two-tailed t-test.
  2. MMSE mini-mental state examination, UPDRS unified Parkinson’s disease rating scale.
Back to article page